Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 6, 2012, Pages 775-782

  Liu, Xiangrui ^a,c   Sun, Jiabei ^a,b   Chen, Xiaomei ^a   Wang, Shanshan ^a   Scott, Hannah ^c   Zhang, Xuan ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b University of Macau   (Macao)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

anti tumour efficacy; paclitaxel; pharmacokinetics; solid dispersion; tissue distribution

Indexed keywords

CREMOPHOR; PACLITAXEL; POVIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISPERSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; LD 50; LOW DRUG DOSE; MALE; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; OVARY CANCER; RAT; SOLID DISPERSION; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CELL LINE, TUMOR; DRUG CARRIERS; FEMALE; GLYCEROL; HUMANS; LETHAL DOSE 50; MALE; MICE; MICE, INBRED ICR; MICE, NUDE; NEOPLASMS; PACLITAXEL; PHYTOTHERAPY; PLANT PREPARATIONS; POVIDONE; RATS; RATS, SPRAGUE-DAWLEY; TAXUS; TISSUE DISTRIBUTION;

EID: 84862786586     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01471.x     Document Type: Article

References (24)

1. Rowinsky EK, et al,. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990; 82: 1247-1259. (Pubitemid 20239995)
2. Wall ME, Wani MC,. Camptothecin and taxol: discovery to clinic-thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1995; 55: 753-760.
3. Gelderblom H, et al,. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37: 1590-1598. (Pubitemid 32778603)
4. Howrie DL, et al,. Anaphylactoid reactions associated with parenteral cyclosporine use: possible role of Cremophor EL. Drug Intell Clin Pharm 1985; 19: 425-427. (Pubitemid 15056453)
5. O'Dwyer PJ, et al,. Hypersensitivity reactions to teniposide (VM-26): an analysis. J Clin Oncol 1986; 4: 1262-1269. (Pubitemid 16043878)
6. Park JH, et al,. Toxicity studies of cremophor-free paclitaxel solid dispersion formulated by a supercritical antisolvent process. Arch Pharm Res 2009; 32: 139-148.
7. Singh S, Dash AK,. Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges. Crit Rev Ther Drug Carrier Syst 2009; 26: 333-372.
8. Mita AC, et al,. Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel. Clin Cancer Res 2007; 13: 3293-3301. (Pubitemid 46944915)
9. Kim TY, et al,. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004; 10: 3708-3716.
10. Kim DW, et al,. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 2007; 18: 2009-2014.
11. Stinchcombe TE,. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. Nanomedicine (Lond) 2007; 2: 415-423. (Pubitemid 47365124)
12. Sparreboom A, et al,. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999; 59: 1454-1457. (Pubitemid 29160110)
13. Liu XR, et al,. In vitro and in vivo studies on plasma-to-blood ratio of paclitaxel in human, rabbit and rat blood fractions. Biol Pharm Bull 2008; 31: 1215-1220.
14. Straub JA, et al,. Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850). Pharm Res 2005; 22: 347-355. (Pubitemid 40558492)
15. Serajuddin AT,. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 1999; 88: 1058-1066.
16. Sun JBLXR, et al,. Preparation, physicochemical characterization and cyctotoxicity of solid dispersion of paclitaxel and polyvinylpyrrolidone. J Chin Pharm Sci 2008; 17: 113-117.
17. Zhang C, et al,. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel. Biomaterials 2008; 29: 1233-1241.
18. Sparreboom A, et al,. Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay. Anal Biochem 1998; 255: 171-175. (Pubitemid 28082078)
19. van Zuylen L, et al,. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol 2001; 47: 309-318. (Pubitemid 32640770)
20. Spencer CM, Faulds D,. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994; 48: 794-847. (Pubitemid 24304427)
21. Sparreboom A, Verweij J,. Paclitaxel pharmacokinetics, threshold models, and dosing strategies. J Clin Oncol 2003; 21: 2803-2804; author reply 2805-2806.
22. Gregory RE, DeLisa AF,. Paclitaxel: a new antineoplastic agent for refractory ovarian cancer. Clin Pharm 1993; 12: 401-415. (Pubitemid 23149973)
23. Lorenz W, et al,. Histamine release in dogs by Cremophor E1 and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 1977; 7: 63-67. (Pubitemid 8070781)
24. Crown J, O'Leary M,. The taxanes: an update. Lancet 2000; 355: 1176-1178. (Pubitemid 30172946)